Your browser doesn't support javascript.
loading
Towards a better understanding of light-glucose induced modifications on the structure and biological activity of formulated Nivolumab.
De Diana, Elisabetta; Rizzotto, Elena; Inciardi, Ilenia; Menilli, Luca; Coppola, Marina; Polverino de Laureto, Patrizia; Miolo, Giorgia.
Afiliação
  • De Diana E; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo, 5, 35131 Padova, Italy.
  • Rizzotto E; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo, 5, 35131 Padova, Italy.
  • Inciardi I; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo, 5, 35131 Padova, Italy.
  • Menilli L; IOV, Istituto Oncologico Veneto, IRCCS, Via Gattamelata, 64, 35 128 Padova, Italy.
  • Coppola M; IOV, Istituto Oncologico Veneto, IRCCS, Via Gattamelata, 64, 35 128 Padova, Italy.
  • Polverino de Laureto P; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo, 5, 35131 Padova, Italy. Electronic address: patrizia.polverinodelaureto@unipd.it.
  • Miolo G; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo, 5, 35131 Padova, Italy. Electronic address: giorgia.miolo@unipd.it.
Int J Pharm ; 654: 123926, 2024 Apr 10.
Article em En | MEDLINE | ID: mdl-38401872
ABSTRACT
In the last years, monoclonal antibodies (mAbs) have rapidly escalated as biopharmaceuticals into cancer treatments, mainly for their target specificity accompanied by less side effects than the traditional chemotherapy, and stimulation of reliable long-term anti-tumoral responses. They are potentially unstable macromolecules under shaking, temperature fluctuations, humidity, and indoor and outdoor light exposure, all stressors occurring throughout their production, transport, storage, handling, and administration steps. The chemical and physical modifications of mAbs can lead not only to the loss of their bioactivity, but also to the enhancement of their immunogenicity with increasing risk of severe hypersensitivity reactions in treated patients because of aggregation. The photostability of Nivolumab, the active principle of Opdivo®, has been here studied. The chemical modifications detected by LC-MS/MS after the light stressor showed Trp and Met mono and double oxidations as primary damage induced by light on this mAb. The oxidations were stronger when the mAb was diluted in sterile glucose solution where 5-HMF, a major heat glucose degradation product, acted as singlet oxygen producer under irradiation. However, no significant changes in the mAb conformation were found. On the contrary, formation of a significant extent of aggregates has been detected after shining high simulated sunlight doses. This again took place particularly when Nivolumab was diluted in sterile glucose, thus raising a direct correlation between the aggregation and the oxidative processes. Finally, the biological activity under light stress assessed by a blockade assay test demonstrated the maintenance of the PD-1 target recognition even under high light doses and in glucose solution, in line with the preservation of the secondary and tertiary structures of the mAb. Based on our results, as sterile glucose is mostly used for children's therapies, special warnings, and precautions for healthcare professionals should be included for their use to the pediatric population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nivolumabe / Glucose Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nivolumabe / Glucose Idioma: En Ano de publicação: 2024 Tipo de documento: Article